5F-CUMYL-P7AICA

5F-CUMYL-P7AICA (also known as SGT-263) is a synthetic cannabinoid that is also a new molecular structure in the global market. It is an analogue of 5F-AB-P7AICA, originally developed by the team led by the pharmacologist John W. Huffman at the Clemson University.

Chemistry

5F-CUMYL-P7AICA is a derivative of 2-Amino-3,3-dimethylbutanoic acid, but the synthetic process can lead to an Indazole core, substituted at R1 with a pentyl chain. At the amide moiety, the indazole is substituted at R3 with a cumyl group. A fluorine atom is attached to the terminal carbon of the cumyl group.

Pharmacology

The pharmacology of 5F-CUMYL-P7AICA is not well studied. However, it is known to act as a potent agonist for the CB1 receptor, which could lead to its psychoactive effects. The exact nature of these effects is not known, but they are likely to be similar to other synthetic cannabinoids, which can include feelings of euphoria, altered perception, and adverse effects such as anxiety and paranoia.

Legality

5F-CUMYL-P7AICA is not specifically listed in the legislation of most countries, making it technically legal. However, in the United States, it could be considered an analogue of 5F-AB-P7AICA, which would make it illegal under the Federal Analogue Act. In the United Kingdom, it is considered a Class B drug under the Psychoactive Substances Act.

See also

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman

References

5F-CUMYL-P7AICA Resources
Latest articles Most recent articles Ongoing trials	Wikipedia